Testing the effectiveness of a specific eye drops called Interferon alpha 2b to treat eye surface tumor.

Efficacy of interferon alpha 2b in treatment of ocular surface squamous neoplasia - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2025/07/091933

Enrollment

Registered

2025-07-29

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H058- Other disorders of orbit

Interventions

Intervention1: Intalfa 3 million IU/ml: Reconstituted interferon alpha 2b in distilled water used topically in eye as 1 million IU/ml formulation. Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed cases of Ocular Surface Squamous Neoplasia

Exclusion criteria

Exclusion criteria: Patient already undergoing other ongoing / incomplete treatment were excluded from the study

Design outcomes

Primary

Measure	Time frame
Effectiveness of Interferon alpha 2b in resolution of the OSSN lesion (both clinically and on slit-lamp examination)Timepoint: 6 months of Interferon treatment	—

Secondary

Measure	Time frame
Time to Clinical Resolution Recurrence Rate Partial Response Rate Adverse Effects Timepoint: 6 months	—

Countries

India

Contacts

Public ContactAkash khiyani

Aravind Eye Hospital

preetiliza@gmail.com8332023520

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026